• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

0.8989 -0.0111 (-1.22%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 139,293
Open 0.8827
Bid (Size) 0.8112 (1,100)
Ask (Size) 0.9390 (100)
Prev. Close 0.9100
Today's Range 0.8500 - 0.9000
52wk Range 0.8500 - 5.070
Shares Outstanding 60,533,064
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026
November 19, 2026
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Top US Stock Movers in Today's Session: Gainers and Losers ↗
November 11, 2026
Via Chartmill

Performance

52-Week Range 82.3% below 52-week high
0.8989
0.8552W Low 5.0752W High
1 Week 26.3% below 1-week high
0.851W Low 1.221W High

Lisata Therapeutics, Inc. - Common Stock (LSTA) traded between $0.85 and $5.07 over the past 52 weeks and last traded at $0.90, 82.3% below its 52-week high. Over the past week it ranged between $0.85 and $1.22.

Past 12 Months
-17.5%
-10.6%
-48.9%
-71.9%
-54.1%
-54.1%
1W -$0.19
1M -$0.11
3M -$0.86
6M -$2.30
YTD -$1.06
1Y -$1.06

LSTA was -54.1% over the past year, -71.9% over six months, -54.1% year to date, -17.5% in the last week.

12 Months vs Market
LSTA
-54.1%
DIA
+4.0%
SPY
+4.7%
QQQ
+3.1%
IWM
+8.9%

Over the past 12 months LSTA returned -54.1% versus DIA (Dow) +4.0%, SPY (S&P 500) +4.7%, QQQ (Nasdaq 100) +3.1% and IWM (Russell 2000) +8.9%.

Volume & Liquidity 0.69× 3-mo avg
Today 139,293 3-mo avg 202.0K
1W
177.3K
1M
138.1K
3M
202.0K
6M
223.8K
YTD
183.9K
1Y
167.1K

LSTA most recently traded 139,293 shares against a 3-month average daily volume of 202.0K.

More News

Read More
News headline image
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of
November 09, 2026
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
November 05, 2026
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
October 14, 2026
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
October 08, 2026
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
October 05, 2026
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether BWIN, LSTA, ACVA are Obtaining Fair Deals for their Shareholders
October 04, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
September 24, 2026
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
September 17, 2026
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
August 04, 2026
From Lisata Therapeutics, Inc.
Via GlobeNewswire
These stocks are moving in today's after hours session ↗
July 28, 2026
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
July 21, 2026
Via Chartmill
The market is filled with gapping stocks in Tuesday's session. ↗
July 21, 2026
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
July 21, 2026
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
July 09, 2026
Via Benzinga
News headline image
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
June 10, 2026
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq –
May 14, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether NSA, LSTA, TALK are Obtaining Fair Deals for their Shareholders
May 12, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether SILA, LSTA, ESPR are Obtaining Fair Deals for their Shareholders
May 05, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq -
May 05, 2026
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
May 04, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether TALK, UBFO, LSTA are Obtaining Fair Deals for their Shareholders
March 10, 2026
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
March 06, 2026
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations
February 02, 2026
From Halper Sadeh LLC
Via GlobeNewswire

Frequently Asked Questions

Is Lisata Therapeutics, Inc. - Common Stock publicly traded?
Yes, Lisata Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Lisata Therapeutics, Inc. - Common Stock trade on?
Lisata Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lisata Therapeutics, Inc. - Common Stock?
The ticker symbol for Lisata Therapeutics, Inc. - Common Stock is LSTA on the Nasdaq Stock Market
What is the current price of Lisata Therapeutics, Inc. - Common Stock?
The current price of Lisata Therapeutics, Inc. - Common Stock is 0.8989
When was Lisata Therapeutics, Inc. - Common Stock last traded?
The last trade of Lisata Therapeutics, Inc. - Common Stock was at 11/20/26 04:00 PM ET
What is the market capitalization of Lisata Therapeutics, Inc. - Common Stock?
The market capitalization of Lisata Therapeutics, Inc. - Common Stock is 54.41M
How many shares of Lisata Therapeutics, Inc. - Common Stock are outstanding?
Lisata Therapeutics, Inc. - Common Stock has 54M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap